Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025)
Pyxis Oncology (PYXS) reported Cost of Revenue of $2.4 million for Q4 2025, up 402.74% on a QoQ basis from $475000.0 in Q1 2024.
Pyxis Oncology (PYXS) has 2 years of Cost of Revenue data on file, last reported at $2.4 million in Q4 2025.
- Quarterly Cost of Revenue changed N/A year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 402.74% YoY) and the FY2025 annual result came in at $2.4 million, up 402.74% from the prior year.
- Cost of Revenue rose to $2.4 million in Q4 2025 per PYXS's latest filing, from $475000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $2.4 million in Q4 2025 and bottomed at $475000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 296.00 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.39 Mn |
| Dec 31, 2025 | 2.39 Mn |
| Mar 31, 2024 | 475,000.00 |
| Mar 31, 2024 | 475,000.00 |